VolitionRx Limited (VNRX)
NYSEAMERICAN: VNRX · Real-Time Price · USD
0.600
-0.050 (-7.71%)
Dec 3, 2024, 1:43 PM EST - Market open
VolitionRx Revenue
VolitionRx had revenue of $474.52K in the quarter ending September 30, 2024, with 187.22% growth. This brings the company's revenue in the last twelve months to $1.29M, up 97.50% year-over-year. In the year 2023, VolitionRx had annual revenue of $775.30K with 153.04% growth.
Revenue (ttm)
$1.29M
Revenue Growth
+97.50%
P/S Ratio
41.93
Revenue / Employee
$11,689
Employees
110
Market Cap
55.55M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 775.30K | 468.91K | 153.04% |
Dec 31, 2022 | 306.39K | 216.36K | 240.30% |
Dec 31, 2021 | 90.04K | 76.60K | 570.25% |
Dec 31, 2020 | 13.43K | -3.66K | -21.43% |
Dec 31, 2019 | 17.10K | - | - |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Burning Rock Biotech | 70.15M |
BGM Group | 29.87M |
Forian | 19.71M |
X4 Pharmaceuticals | 1.12M |
Pheton Holdings | 572.29K |
VNRX News
- 18 days ago - VolitionRx Limited (VNRX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 18 days ago - VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update - PRNewsWire
- 25 days ago - VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update - PRNewsWire
- 26 days ago - Volition Appoints Timothy I. Still as Chairman - PRNewsWire
- 4 weeks ago - Multiple studies show Nu.Q® NETs test could predict sepsis patients at risk of deteriorating - PRNewsWire
- 7 weeks ago - Volition to share new 'NETs in sepsis management' data insights at upcoming webinar - PRNewsWire
- 2 months ago - Volition hosts NETs in sepsis management symposium at ESICM Lives 2024 - PRNewsWire
- 2 months ago - Volition Appoints Dr. Ethel Rubin as an Independent Director - PRNewsWire